

-continued

Val	Phe	Val	Tyr	Arg	Asn	Ser	Leu	Cys	Ile	Glu	Asn	Ser	Cys	Ile	Ala
465					470					475					480
Ala	His	Asp	Lys	Arg	Gly	Arg	Tyr	Gly	Thr	Leu	Phe	Thr	Met	Asp	Arg
				485					490					495	
Val	Leu	Thr	Pro	Pro	Met	Gly	Thr	Val	Met	Asp	Val	Leu	Lys	Gly	Asp
			500					505					510		
Asn	Arg	Phe	Ser	Met	Leu	Val	Ala	Ala	Ile	Gln	Ser	Ala	Gly	Leu	Thr
		515					520					525			
Glu	Thr	Leu	Asn	Arg	Glu	Gly	Val	Tyr	Thr	Val	Phe	Ala	Pro	Thr	Asn
	530					535					540				
Glu	Ala	Phe	Arg	Ala	Leu	Pro	Pro	Arg	Glu	Arg	Ser	Arg	Leu	Leu	Gly
545					550					555					560
Asp	Ala	Lys	Glu	Leu	Ala	Asn	Ile	Leu	Lys	Tyr	His	Ile	Gly	Asp	Glu
				565					570					575	
Ile	Leu	Val	Ser	Gly	Gly	Ile	Gly	Ala	Leu	Val	Arg	Leu	Lys	Ser	Leu
			580					585					590		
Gln	Gly	Asp	Lys	Leu	Glu	Val	Ser	Leu	Lys	Asn	Asn	Val	Val	Ser	Val
		595					600					605			
Asn	Lys	Glu	Pro	Val	Ala	Glu	Pro	Asp	Ile	Met	Ala	Thr	Asn	Gly	Val
	610					615					620				
Val	His	Val	Ile	Thr	Asn	Val	Leu	Gln	Pro	Pro	Ala	Asn	Arg	Pro	Gln
625					630					635					640
Glu	Arg	Gly	Asp	Glu	Leu	Ala	Asp	Ser	Ala	Leu	Glu	Ile	Phe	Lys	Gln
				645					650					655	
Ala	Ser	Ala	Phe	Ser	Arg	Ala	Ser	Gln	Arg	Ser	Val	Arg	Leu	Ala	Pro
			660					665					670		
Val	Tyr	Gln	Lys	Leu	Leu	Glu	Arg	Met	Lys	His					
		675					680								

1-89. (canceled)

90. An isolated human hepatocyte, wherein the isolated human hepatocyte endogenously expresses transforming growth factor beta 1 (TGFβ1), fibronectin, and collagen IV.

91. The isolated human hepatocyte of claim **90**, wherein the isolated human hepatocyte is a human hepatic progenitor cell.

92. The isolated human hepatocyte of claim **90**, wherein the isolated human hepatocyte further expresses human leukocyte antigen G (HLA-G).

93. The isolated human hepatocyte of claim **90**, wherein the isolated human hepatocyte recruits CD4⁺Foxp3⁺Treg cells.

94. The isolated human hepatocyte of claim **90**, wherein a plurality of the isolated human hepatocytes is present in a cluster or an aggregate.

95. The isolated human hepatocyte of claim **90**, wherein a plurality of the isolated human hepatocytes forms a tissue of a 3-dimensional structure.

96. The isolated human hepatocyte of claim **90**, wherein a plurality of the isolated human hepatocytes forms a crescent cell mass.

97. A kit comprising the isolated human hepatocyte of claim **90** and a carrier.

98. A pharmaceutical composition comprising the isolated human hepatocyte of claim **90** and a pharmaceutically acceptable carrier.

99. A method of treating a disorder of liver tissue or liver function in a subject in need thereof, comprising administering to the subject a pharmaceutical composition of claim **98**, whereby the disorder is treated.

100. A method of screening a therapeutic compound for use in treatment or prevention of a condition, comprising:

- contacting the isolated human hepatocyte of claim **90**, with the therapeutic compound; and
- detecting an expression level of a biomarker in the isolated human hepatocyte.

101. A method of producing a therapeutic protein, comprising culturing the isolated human hepatocyte of claim **90** in a medium and extracting the therapeutic protein from the medium.

102. A method of regenerating a liver, comprising applying the isolated human hepatocyte of claim **90** to an ex vivo perfusion system to regenerate the liver.

103. A cell therapy, comprising intravenously administering to a subject in need thereof a composition that comprises the isolated human hepatocyte of claim **90**.

104. A method of bioprinting, comprising applying the isolated human hepatocyte of claim **90** to a bioprinting system.

105. A method of generating a tissue scaffold, comprising culturing the isolated human hepatocyte of claim **90** in a medium on a three-dimensional biocompatible substrate to generate the tissue scaffold.